NFATp is one member of a family of transcriptional activators that regulate the expression of cytokine genes. To study mechanisms of NFATp transcriptional activation, we established a reconstituted transcription system consisting of human components that is responsive to activation by full-length NFATp. The TATA-associated factor (TAF II ) subunits of the TFIID complex were required for NFATp-mediated activation in this transcription system, since TATA-binding protein ( Transcription is a highly regulated process of RNA synthesis, the initiation of which is a primary control point in gene expression. In eukaryotes, genes encoding mRNA are transcribed by RNA polymerase II, a multiprotein enzyme. Reconstitution of an in vitro transcription system with purified RNA polymerase II proved to be insufficient for RNA synthesis from promoters, propelling the identification of a phylogenetically conserved set of general transcription factors (TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH) that are necessary for basal transcription (reviewed in reference 45). The assembly of RNA polymerase II and the general transcription factors on promoter DNA leads to the formation of stable nucleoprotein complexes (preinitiation complexes) that are transcriptionally competent in vitro. Preinitiation complex formation can be regulated by the action of activators and repressors. The activities of these distinct regulatory proteins can promote (activators) or repress (repressors) the recruitment of general transcription factors and RNA polymerase II onto promoters, resulting in promoter-specific augmentation or suppression of transcription.
Transcription is a highly regulated process of RNA synthesis, the initiation of which is a primary control point in gene expression. In eukaryotes, genes encoding mRNA are transcribed by RNA polymerase II, a multiprotein enzyme. Reconstitution of an in vitro transcription system with purified RNA polymerase II proved to be insufficient for RNA synthesis from promoters, propelling the identification of a phylogenetically conserved set of general transcription factors (TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH) that are necessary for basal transcription (reviewed in reference 45) . The assembly of RNA polymerase II and the general transcription factors on promoter DNA leads to the formation of stable nucleoprotein complexes (preinitiation complexes) that are transcriptionally competent in vitro. Preinitiation complex formation can be regulated by the action of activators and repressors. The activities of these distinct regulatory proteins can promote (activators) or repress (repressors) the recruitment of general transcription factors and RNA polymerase II onto promoters, resulting in promoter-specific augmentation or suppression of transcription.
Eukaryotic organisms have evolved elaborate mechanisms for the deployment of RNA polymerase II onto specialized promoter elements that can modulate basal promoter strength. Many RNA polymerase II promoters contain one or more of three identified core promoter elements that direct accurate transcription initiation (5) : the TATA box, the initiator element, and the downstream promoter element. In a temporal scheme, TFIID is the first basal factor to bind to a core promoter, serving as a nucleation center for the rest of the transcriptional apparatus (60) . The architecture of TFIID is also phylogenetically conserved, and it appears that TFIID complexes in yeast, Drosophila melanogaster, and humans have a similar complement of subunits (6) . TFIID is a sequence-specific DNA binding general transcription factor consisting of TATA-binding protein (TBP) and 10 to 13 TATA-associated factors (TAF II s) that together can recognize the TATA box, initiator, and downstream promoter elements.
The orchestration of transcriptional activation at mammalian promoters is a dynamic process that involves the recruitment of functional protein complexes in a highly regulated manner. Activators can exert their effects by interacting with components of the transcription machinery, including subunits of the TFIID and mediator complexes (19, 35) , as well as by recruiting chromatin-modifying complexes (63) . In general, it is the activation domains of activators that bind specific components of the transcriptional apparatus. Activation domains display target specificity depending on their amino acid composition and have been categorized as rich in a particular type of amino acid, for example, acidic residues, glutamines, or prolines (58) .
A limiting step in the process of preinitiation complex formation at some promoters in vitro is the recruitment of TFIID, which is a common target of many eukaryotic activators (19) . TFIID binding to promoters is a central event in transcription initiation, regardless of the manner by which the basal transcriptional components are assembled, either following a stepwise assembly or through the recruitment of a holoenzyme (7) . In some cases, upstream activators that interact with TFIID components achieve efficient recruitment of TFIID (28, 54, 62) . Although direct interactions between TBP and activators have been noted, the primary target within TFIID is not TBP but the TAF subunits of the TFIID complex. TAF II s were coined coactivators in recognition of their requirement for activated transcription in in vitro systems (12, 48) . The validity of the coactivator function of TAFs has been firmly established from examples in yeast, Drosophila, and human systems (1) . Recently, the ability of TAF II s to adopt multifunctional roles as components of functionally distinct complexes, including TFIID, SAGA, PCAF, and TFTC, has been demonstrated.
Although TAFs can function as coactivators, other mechanisms of transcriptional activation exist. The mediator complex, which was first identified in yeast and more recently in humans, is also a target of transcriptional activators and serves to coactivate transcription (35) . In the context of chromatin, nucleosome remodeling complexes and histone acetyltransferases, such as CREB-binding protein (CBP), function to coactivate transcription (63) . It is likely that activators can stimulate transcription by many different mechanisms depending upon the conditions and the context of the promoter at which the activator binds.
The nuclear factor of activated T cells (NFAT) family is a family of activators that exert a pivotal effect on the transcriptional regulation of genes encoding immunomodulatory cytokines (reviewed in reference 50). NFATp (NFAT1 or NFATc2) is one member of the NFAT family (39) , which also includes NFATc (NFAT2 or NFATc1), NFAT3 (NFATc4), NFAT4 (NFATc3 or NFATx), and NFAT5 (21, 37, 43) . NFATp, NFATc, and NFAT4, which are activated during immune responses, participate in the activation of T cells (34, 50) . A regulated burst of NFATc activity appears to be critical for proper cardiac muscle cell differentiation during embryogenesis (49) . NFAT3 functions in cardiac hypertrophy (42) . NFAT4 has been implicated in intrathymic development of immature thymocytes (37) . NFAT5, also known as TonEBP, is involved in the transcriptional regulation of osmotic stress response genes (30, 41) .
All NFAT proteins are DNA binding proteins whose DNA binding domains are conserved between family members and phylogenetically within mammalian systems (20, 21, 23, 30, 37) . The DNA binding domains of NFAT proteins, with the exception of NFAT5, are sufficient for cooperative DNA binding in association with Fos-Jun heterodimers (21, 24, 30) , and an X-ray structure revealed contacts between the DNA binding domain of NFAT and the basic leucine zipper domains of c-Fos and c-Jun (9) . In contrast to the well-characterized DNA binding properties of NFAT proteins, less is known of the transactivation properties that are conferred by their activation domains. In the case of NFATp, two activation domains have been mapped to the N-and C-terminal regions flanking the central DNA binding domain using transient transfection assays and in vitro transcription experiments (25, 32) . The Nterminal region of NFATp has been shown to interact with p300 and CBP and is proposed to play a role in transcriptional activation by NFATp in T cells (17) . In general, the C-terminal regions of NFAT proteins exhibit great sequence variation, suggesting the possibility for functional differences between NFAT proteins.
NFAT transcriptional activity is regulated by cycles of dephosphorylation and phosphorylation involving the phosphatase calcineurin and a number of kinases (2, 3, 10, 11, 24, 29, 31, 36, 44, 47, 59, 65) . A conserved regulatory domain located N terminal to the DNA binding domain of NFAT proteins has been shown to confer calcineurin-mediated nuclear localization (2, 33, 36) . NFAT proteins exist as phosphoproteins in various tissues, but their activation in T cells has been investigated most thoroughly. Typically, antigen-stimulated T cells respond by activating a calcium-dependent signaling pathway that promotes the activation of calcineurin (11) . Activated calcineurin dephosphorylates NFAT proteins, which triggers the accumulation of NFAT proteins in nuclei (24, 43, 55) . Treatment of cells with both a calcium ionophore and a phorbol ester mimics conditions conducive for NFAT nuclear accumulation and NFAT-activated transcription (14) .
We discovered and characterized one mechanism by which NFATp activates transcription. Using a combination of protein-protein interaction assays, in vitro transcription experiments, and transient transfection assays we identified a target of NFATp in the general transcription machinery and investigated its role in mediating NFATp activation in vitro and in cells. Our results support a model in which the unique Cterminal region of NFATp binds the TAF II 130 subunit of human TFIID to activate transcription.
MATERIALS AND METHODS
Plasmids and baculoviruses. Plasmid pREP-NFATp was provided by Tim Hoey (Tularik, Inc.) (21) . Plasmids pBS-KS ϩ -NFATp, pVL1392-HAX-NFATp, pBS-KS ϩ -NFATp(NdeI), and pVL-GST-NFATp have been described previously (25) . pBS-NFATp(1-686) and pBS-NFATp(391-921) were generated using single-stranded pBS-KS ϩ -NFATp(NdeI) for site-directed mutagenesis. In the case of pBS-NFATp(1-686) a stop codon was created in the NFATp cDNA after amino acid (aa) 686 using an oligonucleotide of sequence 5Ј-GACGGAGCCC ACGTAAGAATTCGACCCCACTCTG-3Ј. In the case of pBS-NFATp(391-921) a unique in-frame ATG codon contained in an NdeI site was created in place of the codon for aa 390 using an oligonucleotide of sequence 5Ј-CATCT GCAGCATCCATATGACTGCATCCCTC-3Ј. pT␤-NFATp(1-686) and pT␤-NFATp(391-921) were generated by subcloning NdeI-EcoRI fragments from pBS-NFATp(1-686) and pBS-NFATp(391-921), respectively, into plasmid pT␤-STOP (gift of R. Tjian) digested with NdeI and EcoRI. pGEX-NFATp(688-921) was created by using pBS-KS ϩ -NFATp(NdeI) as template DNA in Vent-catalyzed (Promega) PCRs using primers PNF688-NdeI (5Ј-ATCTGGAATTCCAT ATGGAATATGACCCCACTCTG-3Ј) and PNF921-EcoRI (5Ј-ATCTGGAAT TCCTCGGATCAAAGATCACAG-3Ј). This generated a DNA fragment that was digested with NdeI and EcoRI and subsequently ligated with NdeI-and EcoRI-cut pGEX-2TKN (gift of S. Ruppert and R. Tjian). Plasmids used for expression of TAFs have been described previously: pT␤-hTAF II 250 (52), pT␤-dTAF II 30␣ (64), pT␤-dTAF II 30␤ (64), pT␤-dTAF II 110 (22) , and pT␤-dTAF II 150 (61) were provided by R. Tjian and pT␤-hTAF II 130, pT␤-hTAF II 100, and pCMV-hTAF II 130 were provide by N. Tanese (56) .
pNFAT 3 -MLP-G-less, used as template DNA in the in vitro transcription assays, consists of three direct copies of the murine interleukin-4 (IL-4) highaffinity NFAT site (region Ϫ82 to Ϫ64 of the murine IL-4 promoter) upstream of the adenovirus major late core promoter (Ϫ53 to ϩ10) and a 200-bp G-less cassette. To create pNFAT 3 -MLP-G-less a DNA fragment containing the three NFAT sites was recovered after digestion of pNFAT 3 -E1B-CAT (25) with XbaI and was ligated into the XbaI site of p⌬ML200 (gift of J. Parvin) (4, 46) . The reporter plasmid pGL3-NFAT 3 -Luciferase was created by engineering KpnI and SacI sites into the ends of a PCR fragment bearing three NFAT sites from pNFAT 3 -E1B-CAT. The PCR product was digested with KpnI and SacI and ligated into the pGL3-basic luciferase reporter construct (Promega).
pVL1392-HAX-NFATp and pVL-GST-NFATp were individually cotransfected with Baculogold DNA (PharmMingen) into Sf-9 insect cells to produce baculovirus stocks according to standard procedures. Baculoviruses used to express recombinant FLAG-hTAF II 100 and FLAG-hTAF II 130(137-1083) were a gift from N. Tanese. The HA-hTAF II 250 baculovirus was a gift from R. Tjian.
Expression and purification of recombinant NFATp proteins. Recombinant hemagglutinin (HA)-NFATp was purified as previously described (25) . 2 mM PMSF, 1 g of leupeptin/ml, 1.4 g of pepstatin A/ml, and 1 mM DTT). The eluate was spun through a Millex-GV4 filter, frozen in liquid nitrogen, and stored at Ϫ80°C. Glutathione S-transferase (GST) NFATp (in Hi-five cells), FLAG-hTAF II 130 (in Sf-9 cells), FLAGhTAF II 100 (in Sf-9 cells), and HA-hTAF II 250 (in Sf-9 cells) were expressed in the indicated cells using a similar protocol, with the exception that cell lysates were aliquoted and frozen prior to purification on the appropriate affinity resin (see below).
GST-NFATp(688-921) was expressed in Escherichia coli strain XA-90. Cultures transformed with pGEX-NFATp(688-921) were grown in the presence of 100 g of ampicillin/ml in Luria-Bertani broth at 37°C to an optical density of 0.4 at 600 nm before expression was induced by the addition of isopropylthio-␤-Dgalactoside at a 0.6 mM final concentration. After 2 h, cells were harvested and the cell pellet was resuspended in a buffer containing 20 mM Tris (pH 7.9), 20% (vol/vol) glycerol, 1 mM EDTA, 100 mM NaCl, 1 mM DTT, and 0.2 mM PMSF and sonicated with four 20-s pulses. After centrifugation, the supernatant was aliquoted, frozen in liquid nitrogen, and stored at Ϫ80°C.
Protein-protein interaction assays. GST fusion proteins and GST were immobilized by incubating cell extracts with glutathione-Sepharose beads for 2 h at 4°C. Immobilized proteins were washed two times in 10-bead volumes of TGEMD buffer containing 1 M NaCl [TGEMD (1 M NaCl)] followed by two washes in 10-bead volumes of TGEMD buffer containing 0.1 M NaCl [TGEMD (0.1 M NaCl)]. Prior to use in interaction assays, the amount of each protein on the beads was estimated and approximately 0.5 g of total immobilized protein was added to each interaction assay. Input proteins either were made in a rabbit reticulocyte transcription-translation system (TNT; Promega) in the presence of [ 35 S]methionine, were provided by insect cell lysates containing FLAG-hTAF II 130 (see Fig. 3C ), or consisted of purified TFIID and TBP (see Fig. 3D ). Immobilized proteins and extracts containing target (input) proteins were incubated with micrococcal nuclease at 30°C for 10 min. Input proteins were added to the immobilized GST fusion proteins and nutated for 2 h at 4°C. After washing four times with 10-bead volumes of TGEMD (0.1 M NaCl), the bound fraction was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and autoradiography (or phosphorimagery), silver staining, or immunoblotting (as indicated in the figure legends). Similar conditions were used for interaction assays with immunoprecipitated FLAG-hTAF II 130 and NFATp, except that the FLAG-hTAF II 130 was purified on M2 affinity beads (Sigma).
Assembly of partial TFIID complexes. Partial TFIID complexes, hTBPhTAF II 250-hTAF II 130 and hTBP-hTAF II 250hTAF II 100, were assembled in multiple steps (see Fig. 4A ). In summary, the HA-TAF II 250-hTBP complex was preassembled and eluted prior to its addition to the second binding reaction with immobilized FLAG-hTAF II 130 or FLAG-hTAF II 100. First, HA-hTAF II 250 was purified from an Sf-9 extract by nutation with anti-HA antibody immobilized on protein A-Sepharose 4 Fast Flow (Amersham Pharmacia) for 6 h at 4°C. Immobilized HA-hTAF II 250 was washed extensively with TGEMD (1 M NaCl) followed by TGEMD (0.2 M NaCl). Second, a partially purified fraction of human TBP (hTBP) (expressed in E. coli) was added to the immobilized HA-hTAF II 250 and nutated overnight at 4°C. Third, FLAG-hTAF II 130 and FLAG-hTAF II 100 were purified from insect cell extracts by nutation with anti-FLAG M2 affinity beads for 4 h at 4°C. Non-specifically bound proteins were removed by a series of washes in TGEMD (1.0 M NaCl), followed by TGEMD (0.1 M NaCl). Fourth, after washing in TGEMD (0.2 M NaCl) the HA-TAF II 250-TBP complex was eluted in a 2-h nutation with 1 g of HA peptide/l that was resuspended in elution buffer (20 mM Tris [pH 7.9], 20% glycerol, 1 mM EDTA, 5 mM MgCl 2 , 0.2 M NaCl, 0.1% NP-40, 2 mM PMSF, 1 mM DTT, 1 g of leupeptin/ml, 1.4 g of pepstatin A/ml). Fifth, the eluted HA-TAF II 250-TBP complex was added to immobilized FLAG-hTAF II 130 and FLAG-hTAF II 100 and nutated for 6 h at 4°C. Sixth, the beads were washed four times in TGEMD (0.1 M NaCl). Finally, FLAG peptide (Sigma) was used at a final concentration of 0.5 mg/ml in elution buffer to elute the complexes during a 2-h nutation at 4°C. The eluted fractions were spun through a Millex-GV4 filter, frozen in liquid nitrogen, and stored at Ϫ80°C.
In vitro transcription. Transcription reactions using the reconstituted transcription system were performed as previously described (16) , with the following modifications. Each reaction contained 50 ng of NFAT 3 -MLP-G-less template. Where indicated, HA-NFATp (50 ng) was preincubated with promoter DNA for 5 min at 30°C. TFIID, TBP, or partial TFIID complexes were added to reactions at equivalent final molar concentrations (as determined by anti-TBP immunoblotting; 16) and incubated for 15 min at 30°C prior to the addition of the remaining general transcription factors (TFIIA, TFIIB, TFIIE, TFIIF, and TFIIH) and RNA polymerase II. After the addition of the general transcription factors, reactions were incubated at 30°C for 20 min. Nucleoside triphosphates were added and RNA synthesis was allowed to proceed for 20 min at 30°C. Transcription reactions were stopped with 100 l of a solution containing 3.1 M ammonium acetate, 10 g of carrier yeast RNA, and 15 g of proteinase K. After ethanol precipitation, the samples were resolved by 6% denaturing PAGE and analyzed with a PhosphorImager.
Transfection assays. Cos-1 cells were transfected with Lipofectamine reagent (GIBCO) for 6 h at 37°C using 1.3 g of total DNA and 3.2 l of Lipofectamine. Transfections consisted of the following quantities of DNA (see legend to Fig. 5 for amounts used in specific experiments): 50 to 500 ng of pREP4-RSV-NFATp or the parental vector, 100 ng of pCMV-hTAF II 130 or the pCMV parental vector, 1 g of pGL-NFAT 3 -Luc, and 100 ng of pRL-TK-Renilla luciferase reporter. Where indicated, cells were stimulated with 1 M ionomycin (Calbiochem) and 20 g of phorbol-12-myristate-13-acetate (PMA)/ml for various times at 37°C prior to harvest. Cell lysates were prepared by sonication for 5 min at 4°C in 1ϫ lysis buffer (Promega). The dual luciferase reporter assay system (Promega), which includes the analysis of firefly luciferase and Renilla luciferase within a single sample, was used for the quantification of reporter gene expression. Luciferase activities were determined using an EG&G Berthold's Microlumat LB96P luminometer. NFAT-driven firefly luciferase activity was normalized by dividing firefly luciferase units by the units corresponding to Renilla luciferase activity.
RESULTS
To study mechanisms of transcriptional activation by human NFATp we developed a protocol for the expression and purification of recombinant human NFATp containing an N-terminal HA tag in insect cells using a recombinant baculovirus (25) . HA-NFATp was purified from insect cell lysates using anti-HA affinity chromatography followed by elution with an epitope peptide. The purification resulted in a nearly homogenous preparation of HA-NFATp (Fig. 1A) . The recombinant protein was functional in DNA binding on its own as well as in 2) . NFATp was included in reactions as indicated. The DNA template contained three NFAT sites upstream of the adenovirus major late core promoter and a 200-bp G-less cassette. RNA products were recovered and analyzed by denaturing PAGE. The resulting gel was dried and subjected to autoradiography.
VOL. 21, 2001 HUMAN TAF II 130 IS A COACTIVATOR FOR NFATpcooperation with AP-1 proteins, as assessed by DNase I footprinting (25) . TFIID TAFs function as coactivators for NFATp transcriptional activation in a reconstituted transcription system. Analysis of the transcriptional properties unique to NFATp required the creation of an NFAT-responsive promoter for in vitro transcription studies and the development of a human reconstituted transcription system that is responsive to NFATp. In designing an NFATp-responsive DNA template, we positioned three high-affinity NFAT-binding sites upstream of the adenovirus major late core promoter and a 200-bp G-less cassette. For in vitro transcription studies we utilized a system consisting of purified recombinant and native human general transcription factors, including recombinant TFIIA (rTFIIA), rTFIIB, rTFIIE, rTFIIF, native TFIIH (nTFIIH), nRNA polymerase II, and either nTFIID or rTBP. We previously showed that this transcription system is responsive to recombinant NFATp, that NFATp activation using the reporter template is not dependent on AP-1 proteins, and that AP-1 proteins do not contaminate the purified transcription system (25) . The reconstituted transcription system provided us with a tool to study mechanisms of transcriptional activation by NFATp in the absence of AP-1 proteins and allowed us to investigate the roles of TFIID TAFs in NFATp activation.
HA-NFATp activated transcription an average of sevenfold above the basal level in the reconstituted transcription system containing holo-TFIID (Fig. 1B, compare lanes 3 and 4) . Reactions reconstituted with TBP in place of TFIID showed at most a 50% increase over basal transcription (Fig. 1B, lanes 1  and 2) and on average a 20% increase over basal transcription (i.e., 1.2-fold activation). Hence, the TAF subunits of TFIID were required for high levels of transcriptional activation by HA-NFATp. In this transcription system we observe a higher level of basal transcription when using TBP in place of TFIID even though equivalent molar concentrations of TBP and TFIID were used (16) . This is likely to be due to domains present in the TFIID complex that inhibit its binding to DNA, such as the N terminus of TAF II 250 (27) . Titration of TBP to lower levels did not allow a higher level of transcriptional activation by NFATp (data not shown). Control reactions that lacked either TBP or TFIID but were complemented with the activator and all other components of the basal transcription machinery showed no detectable RNA synthesis (data not shown; see Fig. 4D ), indicating that the transcription system is absolutely dependent on an external source of TBP or TFIID. Consistent with current models of transcriptional activation by many mammalian activators, our experiments demonstrate that transcriptional activation by NFATp can be mediated by the TAF subunits of TFIID in vitro.
NFATp binds hTAF II 130 and dTAF II 110. It has previously been observed that activation domains display binding specificity toward distinct TAF subunits of the TFIID complex (19) . We tested NFATp for the ability to interact with TAFs using in vitro protein-protein interaction assays. To perform the interaction assays, we expressed NFATp as a GST fusion protein in insect cells using a recombinant baculovirus. Purified GSTNFATp bound DNA and activated transcription in vitro (25) . As a convenient source of TAFs for the initial round of interaction assays we expressed a variety of Drosophila and human TAFs using in vitro transcription and translation in rabbit reticulocyte lysate. GST-NFATp was immobilized on glutathione-Sepharose beads, mixed with input TAF proteins for several hours, and washed extensively, and bound protein was analyzed by SDS-PAGE and autoradiography. GST-NFATp interacted specifically with Drosophila TAF II 110 (dTAF II 110) but not with dTAF II 30␣, dTAF II 30␤, dTAF II 150, or human TAF II 250 (hTAF II 250) (Fig. 2A) . In all cases, control GST protein that was immobilized failed to interact with input proteins or interacted less well than immobilized GST-NFATp. To further examine the interaction between GST-NFATp and TAFs we obtained expression vectors for two other human TAFs, hTAF II 130 (the homolog of dTAF II 110) and hTAF II 100 (the homolog of dTAF II 80). As shown in Fig. 2B , GST-NFATp interacted with hTAF II 130 but not with hTAF II 100. As an additional test of the interaction between NFATp and hTAF II 130 we immobilized FLAG-hTAF II 130 that was expressed in insect cells on M2 affinity beads. The immobilized FLAG-hTAF II 130 was incubated with HA-NFATp (purified from insect cell lysates). After extensive washing, bound protein was resolved by SDS-PAGE and analyzed by silver staining. As shown in Fig.  2C , NFATp bound immobilized hTAF II 130. Together these results demonstrate that the human and Drosophila homologs of a subunit of TFIID interact with NFATp.
The C-terminal transactivation domain of NFATp is necessary and sufficient for hTAF II 130 interaction. To identify the region of NFATp that interacts with hTAF II 130, in vitro protein-protein interaction assays were conducted using deletion mutants representing N-and C-terminal truncations of NFATp. NFATp(1-686) contains the N-terminal transactivation domain, the calcineurin binding domain, and the DNA binding domain (Fig. 3A) . NFATp(391-921) contains the DNA binding domain and the C-terminal transactivation domain. Along with the full-length version of NFATp, these deletion mutants were in vitro translated in the presence of [ 35 S]methionine. FLAG-hTAF II 130 expressed in insect cells was immobilized on M2 affinity beads, in parallel with control M2 beads that were exposed to an insect cell extract lacking expressed FLAG-hTAF II 130. Full-length and truncated NFATp were added to these beads, and after sufficient mixing, reactions were subjected to a series of washes before analysis by SDS-PAGE and autoradiography (Fig. 3B) . Full-length NFATp and NFATp(391-921) bound to immobilized FLAG-hTAF II 130. In contrast, NFATp(1-686) did not interact with hTAF II 130. Binding was dependent on the presence of hTAF II 130, since control beads that were not exposed to recombinant hTAF II 130 failed to bind NFATp. Our results show that the C-terminal region of NFATp (aa 687 to 921) is required for interaction with hTAF II 130.
Next, we asked if the C-terminal region of NFATp is sufficient to support protein-protein interaction if separated from the rest of the NFATp protein. To address this issue, we expressed and purified GST-NFATp(688-921). GST-NFATp (688-921) and control GST were separately expressed in E. coli, and both were immobilized onto glutathione-Sepharose beads. As a positive control, full-length GST-NFATp and its GST control made in insect cells were tested in parallel reactions. Recombinant hTAF II 130 purified from insect extract was incubated with the immobilized proteins. Proteins that bound to the beads were separated by SDS-PAGE and analyzed by protein immunoblotting with a monoclonal antibody directed against hTAF II 130 (Fig. 3C ). Our results demonstrate that the C-terminal domain of NFATp (aa 688 to 921) was able to bind hTAF II 130 to an extent roughly equal to that of fulllength NFATp. Thus, a region of NFATp represented by aa 688 to 921 is sufficient for interaction with hTAF II 130.
If the interaction between NFATp and hTAF II 130 is relevant to transcriptional activation by NFATp, then the C-terminal region of NFATp should be able to bind to the holo-TFIID complex. To test this we incubated purified holo-TFIID with immobilized GST-NFATp(688-921) and control GST resin. As an additional control, we incubated purified, recombinant TBP with immobilized GST-NFATp(688-921) and control GST resin. Bound protein was analyzed by immunoblotting with anti-TBP and anti-hTAF II 130 antibodies. As shown in Fig. 3D , approximately 50% of the input holo-TFIID bound specifically to the immobilized GST-NFATp(688-921). Recombinant TBP, which lacks the TAF subunits of TFIID, did not bind immobilized GST-NFATp(688-921). Hence, holo-TFIID interacts with the C-terminal domain of NFATp and TAFs are required to observe this interaction.
TAF II 130 is a coactivator for NFATp in vitro. Native mammalian TFIID consists of 10 to 13 TAFs and TBP, whose internal interactions among the subunits have been defined by the efforts of many investigators. In vitro assembly of partial TFIID complexes from recombinant TBP and TAF subunits has previously been accomplished (8) . In fact, the assembly of partial TFIID complexes and their analysis in reconstituted transcription systems has been used as a direct approach for demonstrating the function of individual TAFs as coactivators (8, 15, 26, 57) . To employ this approach as a test of the coactivator function of hTAF II 130 for NFATp, we constructed a partial TFIID complex consisting of hTBP, hTAF II 250, and hTAF II 130. A comparable complex, hTBP/hTAF II 250/ hTAF II 100, sharing all but one component (hTAF II 100 in place of hTAF II 130) was constructed as a negative control. With the exception of hTBP, which was expressed in E. coli, the remaining components were made in insect cells infected with individual baculoviruses for each recombinant protein. hTAF II 250 was N-terminally tagged with an HA epitope, and both hTAF II 100 and hTAF II 130 were N-terminally FLAG tagged. The general scheme for complex assembly and elution is depicted in Fig. 4A . Complexes were assembled in a step-wise manner as follows. In the first phase, the hTBP/ hTAF II 250 complex was preassembled on anti-HA affinity resin by immobilizing HA-TAF II 250 first and adding recombinant TBP next, prior to the elution of the complex with an HA-epitope peptide. At this point, the hTBP/hTAF II 250 complex was analyzed by SDS-PAGE (data not shown) and tested for activity in basal and NFATp-activated transcription (Fig.  4B) . As anticipated, the hTBP/hTAF II 250 complex supported basal transcription at levels similar to holo-TFIID but did not support high levels of NFATp transcriptional activation. In the second phase of the assembly reactions (Fig. 4A) , recombinant FLAG-hTAF II 130 and FLAG-hTAF II 100 were immobilized on M2 beads. The preassembled hTBP-hTAF II 250 complex was added next, allowing association with either FLAGhTAF II 130 or FLAG-hTAF II 100. The final forms of the complexes were eluted with a FLAG-epitope peptide. Analysis of the constituents of both complexes by SDS-PAGE and silver staining indicated that individual subunits were incorporated at comparable levels into the partial TFIID complexes (Fig. 4C) .
Using the reconstituted transcription system described earlier, we compared the ability of NFATp to activate transcription in reactions reconstituted with either TFIID, the hTBP/hTAF II 250/hTAF II 130 complex, or the hTBP-hTAF II 250-hTAF II 100 complex (Fig. 4D) . Consistent with the results of the interaction assays, the hTBP-hTAF II 250-hTAF II 130 complex supported an average of sixfold transcriptional activation by NFATp (compare lanes 5 and 6). In contrast, reactions reconstituted with the partial TFIID complex containing hTAF II 100 in place of hTAF II 130 were not able to support significant NFATp-activated transcription (average activation of 1.2-fold; compare lanes 3 and 4), consistent with the lack of observed interaction between NFATp and either hTAF II (40) while repressing or having a dominant-negative effect on activation by other activators (38, 53) . To conduct similar experiments, we constructed an NFAT-responsive reporter by introducing three NFAT sites upstream of the E1B-TATA core promoter and the firefly luciferase gene. We tested this reporter for responsiveness to overexpressed NFATp in Cos-1 cells. Transfection efficiency was monitored in all samples by cotransfection with a pRT-TK-Renilla luciferase plasmid. As expected, increasing amounts of NFATp induced firefly luciferase expression from the NFAT-dependent reporter; however, a control template lacking NFAT sites failed to respond (data not shown).
To assess the effect of hTAF II 130 overexpression on NFATdirected transcriptional activation, Cos-1 cells were cotransfected with expression plasmids for NFATp and hTAF II 130. Portions of the transfected cell cultures were stimulated with ionomycin and PMA for various amounts of time (6, 12 , and 24 h) or were unstimulated. Localization of NFATp is not dependent on ionomycin treatment in Cos cells (31) ; however, it was applied to cells to simulate the physiological conditions that may be conducive to NFAT-mediated activation. Similarly, cells were treated with PMA to activate PMA-responsive effectors that may support NFAT-mediated activation in vivo.
Firefly luciferase values were normalized by Renilla luciferase values for each sample. As shown in Fig. 5A , NFATp caused a 6-to 10-fold increase in luciferase activity that did not depend on treatment with PMA and ionomycin. Expression of hTAF II 130 did not affect luciferase activity in the absence of NFATp overexpression; however, expression of hTAF II 130 significantly decreased NFATp-mediated luciferase activity under all conditions tested. The amount of hTAF II 130 expression vector added to the transfections did not decrease the expression level of Renilla luciferase, which is driven by the thymidine kinase promoter (data not shown). Furthermore, the repressive effect of hTAF II 130 overexpression on NFATp activation was overcome by increasing the amount of NFATp expression plasmid added to transfections (Fig. 5B) . We conclude that overexpressed hTAF II 130 acts as a dominant-negative inhibitor of NFATp-activated transcription in cells.
DISCUSSION
Here we present evidence supporting a mechanism by which NFATp potentiates transcriptional activation by direct interaction with hTAF II 130, a component of the TFIID complex. Such targeting events by activators to their TAF coactivator partners are thought to enhance the recruitment and/or stabilization of TFIID to promoters. Our model of a mechanism of NFAT-mediated activation is strongly supported by three key results: (i) the presence of a direct and specific interaction between NFATp and hTAF II 130 in vitro, (ii) the ability of hTAF II 130 to serve as a coactivator for NFATp in vitro, and (iii) the observation that overexpressed hTAF II 130 repressed NFATp activation in cells. This study is the first to demonstrate a mechanism of activation by any NFAT family member using a cell-free system.
The C-terminal domain of NFATp (aa 688 to 921) is both necessary and sufficient to bind hTAF II 130. This region contains a glutamine-rich activation domain. Since hTAF II 130 and dTAF II 110 have been found to bind Gln-rich activation domains of other activators such as CREB and SP-1 (13, 22, 53, 56) , Gln-rich regions of the C-terminal domain of NFATp may be important in hTAF II 130-mediated recruitment of TFIID. Human NFATp exists as predominately two isoforms (B and C) that are splice variants, with differences only in the extreme tail end of these proteins (aa 908 to 921 and 908 to 925, respectively) (50). In the studies described here we used the B isoform of NFATp. It remains to be determined if the hTAF II 130-dependent mode of activation characterized here is also applicable to the C isoform of NFATp. In either case, the amino acids shared in the C-terminal regions of the B and C isoforms of NFATp (aa 688 to 908) are unique to NFATp and are not found in other NFAT proteins, and hence it is possible that interaction with hTAF II 130 is a unique property of NFATp. Future studies will be aimed at testing for TAF interactions with other NFAT family members.
When hTAF II 130 was overexpressed in cells, we observed a dominant-negative effect on NFAT-activated transcription. This phenomenon has previously been observed for a number of viral and cellular activators in mammalian cells. Transcrip- -TAF II 250-TAF II 130 and TBP-TAF II 250-TAF II 100 , were substituted for immunopurified TFIID in a reconstituted transcription assay in the absence and presence of NFATp. RNA products were purified, resolved by denaturing PAGE, and subjected to PhosphorImager analysis. tional activation by SP-1 and CREB, which can individually associate with hTAF II 130 and dTAF II 110 in vitro, was inhibited by overexpression of hTAF II 130 in mammalian cells (53) . Similarly, it has been shown that E1A binds directly to hTAF II 130 in vitro and that overexpression of the hTAF II 130 C-terminal domain repressed E1A-mediated transcriptional activation in cells in a dosage-dependent manner (18, 38) . The authors of these studies have offered the following explanations for the dominant-negative effect of hTAF II 130 overexpression that can also be applied to the NFATp system. It is possible to envision promoter-bound activators preferentially binding the more abundant overexpressed hTAF II 130 instead of recruiting the entire TFIID complex. This would result in the loss of transcriptional activation. It is equally conceivable that hTAF II 130 overexpression causes a diluting effect of another essential factor that functions in hTAF II 130-mediated transcriptional activation by these activators. Our observations support the first explanation provided above in that the repressive effect of hTAF II 130 overexpression on NFATp activation was overcome by increasing the amount of NFATp expression plasmid added to transfections.
Promoters, such as the IL-2 promoter, that are regulated by NFAT often contain multiple NFAT sites, many of which are part of composite elements to which NFAT and AP-1 bind cooperatively (51) . It is likely that NFATp affects transcription at many levels in cells by targeting the TAF II 130 subunit of the TFIID complex as well as non-TFIID factors. Our results suggest that if additional coactivators for NFATp exist in cells, they are factors other than the general transcription factors or the RNA polymerase II subunits, since TBP-supported transcription reactions were nonresponsive to NFATp. For example, the coactivators p300 and CBP have been found to bind NFATp (17) .
Here we have shown that NFATp binds the TAF II 130 subunit of human TFIID and that hTAF II 130 is a coactivator for NFATp in a reconstituted transcription system. These in vitro studies provide the first biochemical analysis of mechanisms of transcriptional activation by the NFAT family of transactivators. We also found that overexpressed hTAF II 130 blocked NFATp-activated transcription in cells. It seems likely that the interaction between NFATp and hTAF II 130 plays a role in transcriptional activation at endogenous promoters; however, the identity of these promoters and the exact role of this interaction in the temporal and cell-type-specific expression of NFATp-responsive promoters awaits further study. Transfection assays were performed as described above except that the amounts of NFATp expression vector used were 0, 100, 300, and 500 ng. Cells were stimulated with PMA and ionomycin for 6 h.
VOL. 21, 2001 HUMAN TAF II 130 IS A COACTIVATOR FOR NFATp 3511
